Locatim (--) - Oral solution
Locatim (--) - Oral solution
Authorised
- Immunoglobulins against Escherichia coli F5 antigen, Bovine
Product identification
Medicine name:
Locatim (--) - Oral solution
Active substance:
- Immunoglobulins against Escherichia coli F5 antigen, Bovine
Target species:
-
Cattle (newborn calf)
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Immunoglobulins against Escherichia coli F5 antigen, BovinePresentation_strength:≥2.8 log₁₀ Reference:Hse Comments:Immunoglobulins G against E. coli F5 (K99) adhesin contained in bovine concentrated lactoserum Index:0
Pharmaceutical form:
-
Oral solution
Withdrawal period by route of administration:
-
Oral use
- Cattle (newborn calf)
-
Not applicable0dayZero days
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI02AT01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Package description:
- Packaging:Bottle (glass), Package_size:1 bottle, Content:60 ml
- Packaging:Bottle (glass), Package_size:48 bottles, Content:60 ml
- Packaging:Bottle (glass), Package_size:12 bottles, Content:60 ml
- Packaging:Bottle (glass), Package_size:24 bottles, Content:60 ml
- Packaging:Bottle (glass), Package_size:6 bottles, Content:60 ml
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Complete application (stand-alone) - Council Directive 81/851/EEC
Marketing authorisation holder:
- Biokema Europe
Marketing authorisation date:
Manufacturing sites for batch release:
- Biokema Anstalt
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 15/11/2022
Bulgarian (PDF)
Published on: 15/11/2022
Croatian (PDF)
Published on: 15/11/2022
Czech (PDF)
Published on: 15/11/2022
Danish (PDF)
Published on: 15/11/2022
Dutch (PDF)
Published on: 15/11/2022
Estonian (PDF)
Published on: 15/11/2022
Finnish (PDF)
Published on: 15/11/2022
French (PDF)
Published on: 15/11/2022
German (PDF)
Published on: 15/11/2022
Greek (PDF)
Published on: 15/11/2022
Hungarian (PDF)
Published on: 15/11/2022
Icelandic (PDF)
Published on: 15/11/2022
Italian (PDF)
Published on: 15/11/2022
Latvian (PDF)
Published on: 15/11/2022
Lithuanian (PDF)
Published on: 15/11/2022
Maltese (PDF)
Published on: 15/11/2022
Norwegian (PDF)
Published on: 15/11/2022
Polish (PDF)
Published on: 15/11/2022
Portuguese (PDF)
Published on: 15/11/2022
Romanian (PDF)
Published on: 15/11/2022
Slovak (PDF)
Published on: 15/11/2022
Slovenian (PDF)
Published on: 15/11/2022
Spanish (PDF)
Published on: 15/11/2022
Swedish (PDF)
Published on: 15/11/2022
How useful was this page?:
